Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

Completed · Phase 1 · Has a placebo group

Conditions studied: Parkinson's Disease

In brief

The purpose of this research study is to measure the safety (side effects) of an Omega 3 Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary movements) in Parkinson 's disease (PD).

Key facts

Study ID

NCT01563913

Run by

VA Office of Research and Development

People needed

33

Starts

2012-10-01

Expected to finish

2016-06-01

Last updated by the study team

2018-06-29

Who can join

Age: 21 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with Parkinsons disease
• No levodopa (Sinemet) treatment or prior exposure to levodopa

You may not qualify if…

• Prior exposure to levodopa
• Unable to stand for 1 minute without aid
• Sensory deficits on feet
• Significant cognitive impairment
• Current use of dopamine receptor blocking medications (depakote, lithium, amiodarone, tetrabenazine, metoclopramide, dronabinol)
• Current fish oil or lutein supplementation
• Allergy to soy

Where it is running

• VA Portland Health Care System, Portland, OR — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.